Navigation Links
Single Sugar Enables Antibody to Treat Inflammation

For years, researchers have struggled to understand how IVIG worked. Its ability to treat autoimmune diseases seemed to be an apparent contradiction.//

Intravenous immunoglobulin (IVIG) is a complex mixture of IgG antibodies made from human plasma that contains the pooled antibodies from thousands of people, and is only FDA-approved to treat a few assorted conditions; nonetheless, practitioners have used it off-label with varied success in patients with lupus, arthritis and asthma, among other autoimmune disorders. In the body, the antibodies in plasma act as part of the immune response to identify and deactivate foreign invaders. When they begin attacking the body's own cells, the same protective immunoglobulins (known as IgG antibodies) can cause autoimmune disorders like lupus, arthritis and asthma. And yet, when IVIG is infused into people with those exact autoimmune conditions, it calms inflammation rather than causes it.

Jeffery Ravetch, Theresa and Eugene M. Lang Professor and head of Rockefeller's Leonard Wagner Laboratory of Molecular Genetics and Immunology, was struck by this inconsistency. "If IgG triggers autoimmune disease, how could it be pathogenic and therapeutic?" he asked. "We call it the IgG paradox." Six years ago he started an investigation into exactly how IVIG worked, and what he's discovered could one day lead to a whole new class of therapeutics. In a paper published in the August 4 issue of the journal Science, Ravetch and his colleagues, Falk Nimmerjahn and Yoshi Kaneko, explain what makes IVIG effective: A small fraction of the IgG antibodies in the IVIG solution carry a sugar called sialic acid that is required for its protective ability.

IgG antibodies bind to and activate specific immune cells, with different forms or "subclasses" binding to specific receptors (called Fc receptors) on the immune cell's surface. Antibody subclasses have different abilities to induce inflammation in the body by virt
'"/>




Page: 1 2 3

Related medicine news :

1. Single gene analysis for diagnosis of a range of blood disorders
2. Single drug for bipolar disorder
3. Treating Testicular Cancer With A Single Dose Of Chemotherapy
4. Decreasing Multiple Births By Single Embryo Transfers
5. Single gene skin cancer cause
6. Drug Firms To Produce Single Pill AIDS Treatment
7. Malaria May Gain Resistance To Single Drug Prescriptions
8. Single Women with Baby Cravings Can Actually Cradle their Own, Courtesy NHS
9. Thai Doctors Removed 421 Kidney Stones From A Single Person
10. Single Dose Of Azithromycin Could Cure Trichiasis
11. Effects Of Certain Food Related To Single Pain Receptors

Post Your Comments:
(Date:12/3/2009)...sue of Deutsches rzteblatt International contain...xperience with the novel influenza A virus (H1N1/0...t of the pandemic. Ralf Winzer and his coauthors f...ely evaluated data from a large clinical cohort of...2009; 106[47]: 770-6). Their medical-scientific ar...
(Date:12/3/2009)... 450 Deaths a day is still too many - s...k. , Atlanta, GA, Geneva,...3, 2009 -- The Measles Initiative announced today ...2000 and 2008, from an estimated 733 000 in 2000 t...perts warn of a resurgence in measles deaths if va...
(Date:12/3/2009)... Nutra Pharma will be conducting a webi...squo;s over-the-counter and prescription treatment... Plantation, FL (Vocus) Decem... biotechnology company that is developing treatmen...le Sclerosis (MS), has announced today that it wil...
(Date:12/3/2009)...ANTA ROSA, Calif., Dec. 3 Osseon T...eerable and curvable bone cement delivery needle) ...l) systems for percutaneous vertebral augmentation...alth Canada for marketing and clinical use in Cana... corresponds to FDA approval in the United States,...
(Date:12/3/2009)...AScientists at Boston Biomedical Research Institut...ound that combining two chemicals, one of which is...stroy a variety of protein structures known as amy...brain disorders such as Alzheimer,s, Huntington,s,... in the current issue of Nature Chemical Biology ...
Breaking Medicine News(10 mins):Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 2Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 3Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 4Health News:Nutra Pharma Announces Upcoming Webinar to Discuss the Company's Over-the-Counter (OTC) and Prescription Treatments for Chronic Pain 2Health News:Nutra Pharma Announces Upcoming Webinar to Discuss the Company's Over-the-Counter (OTC) and Prescription Treatments for Chronic Pain 3Health News:Osseon Therapeutics, Inc. Announces it has Received Canadian Medical Device Licenses From Health Canada 2Health News:Green tea chemical combined with another may hold promise for treatment of brain disorders 2
... Dr. Wayne Andersen to discuss weight management...uot; which is helping thousands maintain permanent...le-Dublin, Ohio (PRWEB) April 30, 2009 -- Dr. Wayn...three free seminars in the Westerville-Dublin area...
... G1G Travel Insurance and Student Funding Group ...l safely; Tuition Fee protection programs also add...se, CA (PRWEB) April 30, 2009 -- With a rise in in...udent Funding Group (StuFund) to offer newly creat...
...and, Ore.) A brief intervention program consisti...ne calls boosted by tenfold the number of women c...the findings of a Kaiser Permanente Center for Hea...intervention programs can be effective in increasi...
...illion in Total Revenues for the Quarter , , SAN ... Realty Trust, Inc. (NYSE: BMR ), a real estate ...to the Life Science Industry(R), today announced o...ter were $94.0 million, up 39.5% from $67.4 millio...
... VA,s Office of Research and Development is at th...eatments based on new knowledge about the role of ... to study genomics--the use of patients, individua...ed network of basic research and clinical applicat...
...ining the mechanism of a novel therapy that uses m... showed the treatment to be a promising alternativ...nial magnetic stimulation, or TMS. Study findings...ntrolled clinical study by Ohio State University M...
Other Medicine News:Health News:Physician and Author to Share Clinically Proven System for Permanent Weight Loss and Optimal Health in Westerville and Dublin, Ohio Areas 2Health News:New G1G Student Medical Insurance and Student Fee Protection Now on StuFund Web Site 2Health News:New G1G Student Medical Insurance and Student Fee Protection Now on StuFund Web Site 3Health News:Women 10 times more likely to do breast self-exams correctly with intervention, KP study finds 2Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 2Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 3Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 4Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 5Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 6Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 7Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 8Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 9Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 10Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 11Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 12Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 13Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 14Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 15Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 16Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 17Health News:Video: Turning Hope Into Reality - Genomics Research at the VA 2Health News:New therapy based on magnetic stimulation shows promise for non-drug treatment for migraine 2
(Date:12/3/2009)...TER, N.Y., Dec. 3 Virtua...er of quantitative imaging for clinical trials, an...ethod for 4D Reconstruction and Visualization" rec...pics, Vice President of Technology and Product Dev...ed that Japan has recognized the uniqueness of Vir...
(Date:12/3/2009)..., ROTTERDAM, The Netherlands, December 3 /PR...ny focused on the discovery and development of hum...y(TM) platform, today,announced the successful sec.... The Company raised an additional EUR 3.0 million...investors, Credit Agricole Private Equity and,VIB ...
(Date:12/2/2009)... NEW YORK, Dec. 2 Reportlinker.com...ailable in its catalogue: ,, Cardiac Pacemake...eportlinker.com/p0164335/Cardiac-Pacemakers---A-Wo...constitute a major segment in a rapidly expanding ...ac pacemakers market is characterized by relativel...
Breaking Medicine Technology:VirtualScopics Receives Issuance in Japan of Prominent Patent 2VirtualScopics Receives Issuance in Japan of Prominent Patent 3arGEN-X Concludes EUR 12.5 Million Series A Financing Round 2arGEN-X Concludes EUR 12.5 Million Series A Financing Round 3arGEN-X Concludes EUR 12.5 Million Series A Financing Round 4Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 2Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 3Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 4Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 5Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 6Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 7Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 8Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 9Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 10ATS Medical Announces Third Quarter 2009 Earnings Release Date and Conference Call 5713 1ATS Medical Announces Third Quarter 2009 Earnings Release Date and Conference Call 5713 2MedPlus Maintains Top Ranking in KLAS Industry Report 5710 1MedPlus Maintains Top Ranking in KLAS Industry Report 5710 2MedPlus Maintains Top Ranking in KLAS Industry Report 5710 3MedPlus Maintains Top Ranking in KLAS Industry Report 5710 4Reportlinker Adds Outsourcing Preclinical Studies to China 5707 1Reportlinker Adds Outsourcing Preclinical Studies to China 5707 2Reportlinker Adds Outsourcing Preclinical Studies to China 5707 3Reportlinker Adds Outsourcing Preclinical Studies to China 5707 4Reportlinker Adds Outsourcing Preclinical Studies to China 5707 5Reportlinker Adds Outsourcing Preclinical Studies to China 5707 6
...r Similar to Seven-Day in, Achieving Red Blood Cel...t in All MDS Patients Tested...Hematology (ASH) Meeting, ATLANTA, Dec. 11 Pharm...nterim data from a Phase 2 clinical trial,evaluati... Vidaza(R),(azacitidine for injection) that demons...
...city With Equivalent Complete Re...erapeutics, Inc.,(CTI) (Nasdaq and MTAX: CTIC) ann...II/III randomized study comparing CPOP-R to CHOP-R...essive non-Hodgkin,s lymphoma,(NHL) showed patient...(grade 3/4) toxicities including severe infection ...
Other Medicine Technology:MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 2MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 3MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 4MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 5MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 6Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 2Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 3Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 4Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 5
Multi Dop T1
EZ-Dop
...owerful automated system capable of handling any c...m 6 user-programmable test protocols to begin a fu...tests not included in the comprehensive list of au...ler, PVR and PPG instrument modes. Provides high f...
CD Horizon M10
Medicine Products: